Approval for DC Bead for liver cance by the State Food and Drug Administration (FDA in China) is possible in 2013. A long process but, news of progress here would legitimize their work and relationships in China. It could get the SP going up quickly.
SCLN has confidence in their sales force. You can see it in their use of cash that signals that future sales, and cash from them, will be available. NovaMed is now ingrained into the company and the sales distribution is a successful and working operation. Sanofi, Pfizer and Baxter will need to re-up and increase their collaborations withh SCLN.
This company has legs for growth and increasing the SP.